GlobeNewswire

Kyntra Bio to Report Third Quarter 2026 Financial Results
13/11/2026
SAN FRANCISCO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce third quarter 2026 financial results on Monday, November 16 after market close. Kyntra Bio will also conduct a conference [...]
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
13/11/2026
INLIGHT Phase 1 data continue to support WVE-007’s novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen Six-month data from [...]
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
13/11/2026
BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present [...]
Sienna Announces November Dividend
13/11/2026
MARKHAM, Ontario, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Cannabix Technologies to Present Multi-Drug Breath Technology at BC Centre for Excellence on Substance Use Disorders
13/11/2026
VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana, multi-drug, and alcohol breath [...]
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
13/11/2026
DENVER, Nov. 13, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) reaches an important clinical-development milestone today as it presents updated findings from two investigational [...]
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
13/11/2026
New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families Findings further support [...]
Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
13/11/2026
First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment New translational data expanded SIL204 [...]
UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
13/11/2026
Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and [...]
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
13/11/2026
AlterG revenue increased 18% year-over-year to $3.6 million, driven by higher U.S. unit shipments, service revenue and average selling prices The Company is advancing its transition of ReWalk to a capital-efficient [...]
Sol y Vida Recognizes National Diabetes Awareness Month, Honoring the Families and Communities Leading the Way on Early Detection
13/11/2026
Bilingual clinic joins the Latino Diabetes Association in encouraging Latino families to learn their risk and talk with a doctor LOS ANGELES, Nov. 13, 2026 (GLOBE NEWSWIRE) -- In recognition of National Diabetes [...]
COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
13/11/2026
TORONTO, ONTARIO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) today reported its financial and operating results for the third quarter ended [...]
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
13/11/2026
Primary efficacy endpoint achieved based on preliminary results from a November 5 th data evaluation Topline results for the completed study, along with additional study details including statistical analysis of the [...]
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
13/11/2026
Transaction led by Frazier Life Sciences with participation from new and existing funds REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra [...]
Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
13/11/2026
European Commission to make final decision on arimoclomol MAA following negative CHMP opinion BOSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial- [...]
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE)
13/11/2026
Positive recommendation is based on phase III ALLEGORY study data showing Gazyva/Gazyvaro significantly reduced disease activity in patients with SLE compared with placebo 1 If approved, Gazyva/Gazyvaro would be the [...]
Henrik Juuel to Step Down as Chief Financial Officer of Bavarian Nordic in 2027
13/11/2026
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that Henrik Juuel has informed the Board of Directors of his decision to step down as Chief Financial Officer. Henrik Juuel will [...]
Bavarian Nordic Reports Strong Travel Health Growth in the Third Quarter and Confirms Solid Momentum for the Rest of the Year
13/11/2026
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the third quarter and first nine months of 2026. Financial highlights [...]
Bavarian Nordic Launches Next Tranche of DKK 750 Million Share Buy-Back Program
13/11/2026
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the share buy-back program announced on August 21, under which the Company intends to repurchase own shares [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum